SEC Filing | Ardelyx, Inc.
Ardelyx
Scripts : r/ARDELYX
Positive FDA AdCom votes for Ardelyx's tenapanor
ARDX / Ardelyx, Inc. - Put/Call Ratio, Options Sentiment, Unusual Options Activity
Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial | PDF | Chronic Kidney Disease | Therapy
Ardelyx on X: "Press Release: FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor) Read more here: https://t.co/drMd3jYvKl https://t.co/DYmGNsa9Nt" / X
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript
Ardelyx Inc.(NASDAQ: ARDX)-Can it Continue to Outdo Estimates?
Ardelyx, Inc. (ARDX) Stock Price, Quote & News - Stock Analysis
Ardelyx
Ardelyx wins FDA approval for phosphate absorption inhibitor - Pharmaceutical Technology
Ardelyx Inc Stock News | ARDX Company Stock News and Press Releases | FinancialContent Business Page
Ardelyx, Inc. on LinkedIn: Press Release: Ardelyx Announces Poster Presentations on XPHOZAH®…
Ardelyx
Adding Ardelyx (ARDX) $1.57 to Watch List. | Internet | Biotech Stock Review
Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
Ardelyx Prepares for Battle with FDA Over Rejected CKD Drug | BioSpace
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ardelyx, Inc. (ARDX) Investigation
Ardelyx Inc Stock News | ARDX Company Stock News and Press Releases | FinancialContent Business Page
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities | Ardelyx, Inc.
Hyperphosphatemia Pipeline Insight Report 2023 (Updated)
ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Ardelyx Stockholders and Encourages Investors to Contact the Firm | Business Wire
Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
News & Events | Ardelyx, Inc.
Ardelyx Grants Stock Options & RSUs to New Employees
